1998
DOI: 10.1097/00045391-199805000-00010
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Montelukast on Single-Dose Theophylline Pharmacokinetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2001
2001
2010
2010

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 0 publications
0
9
0
Order By: Relevance
“…[63] In adults, the pharmacokinetics of theophylline, [64] the (R)-or (S)-enantiomer of warfarin, [65] digoxin, [57,66] terfenadine [67] or fexofenadine [57] were unaltered by concomitant montelukast administration. The C max and AUC ∞ of a single 10mg oral dose of montelukast were reduced by 37.5 and 21%, respectively, in healthy, adult volunteers who also received phenobarbital (phenobarbitone) [100 mg/day for 14 days], but dosage adjustments are not recommended.…”
Section: Studies In Humansmentioning
confidence: 99%
“…[63] In adults, the pharmacokinetics of theophylline, [64] the (R)-or (S)-enantiomer of warfarin, [65] digoxin, [57,66] terfenadine [67] or fexofenadine [57] were unaltered by concomitant montelukast administration. The C max and AUC ∞ of a single 10mg oral dose of montelukast were reduced by 37.5 and 21%, respectively, in healthy, adult volunteers who also received phenobarbital (phenobarbitone) [100 mg/day for 14 days], but dosage adjustments are not recommended.…”
Section: Studies In Humansmentioning
confidence: 99%
“…In a 12-week study, montelukast demonstrated a faster onset of action and a greater initial effect than beclomethasone. 29 While both drugs significantly improved FEV 1 , PEFR, the number of asthma control days, and the number of asthma exacerbation days, the overall average effect was greater for beclomethasone compared with montelukast. Figure 4 shows the percentage of patients that responded for each increment of FEV 1 change; 42% of the montelukast recipients and 50% of beclomethasone recipients had an improvement in FEV 1 of at least 11% from baseline.…”
Section: L I N I C a L S T U D I E S I N A D U L T Smentioning
confidence: 93%
“…However, when investigated in vivo, using the CYP2C8-dependent substrate, pioglitazone, this inhibitory potential of montelukast was not realized, with negligible impact on the pharmacokinetics of the drug (Jaakkola et al, 2006). There also does not appear to be any inhibitory effects in vivo on CYP1A2, as assessed by theophylline metabolism (Malmstrom et al, 1998), or CYP2C9, as assessed by warfarin metabolism (Van Hecken et al, 1999), at least not at clinical doses of montelukast.…”
Section: Metabolism-based Interactions Involving Drugs Used To Treat mentioning
confidence: 99%